Genomic Analysis of Pediatric Bone Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Stanford University
Information provided by (Responsible Party):
Stanford University Identifier:
First received: January 11, 2010
Last updated: April 22, 2016
Last verified: April 2016
To determine whether gene expression analysis of primary tumor samples before and after chemotherapy are predictive of long-term survival in pediatric patients with bone sarcomas (Ewings sarcoma (ES) and Osteosarcoma(OS)).

Bone Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Genomic Analysis of Pediatric Bone Tumors (Other Title: Pediatric Bone Tumor Biology Study)

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • % necrosis post chemotherapy [ Time Frame: his is measured at the time of sample collection since we are looking for % necrosis in the sample we are collecting ] [ Designated as safety issue: No ]
  • overall survival and event free survival [ Time Frame: This is measured at the time the patient dies, or at the time when patient relapses from their disease. There is no set time since this outcome is individually assessed. ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
tumor samples and blood

Estimated Enrollment: 150
Study Start Date: August 2007
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with bone x-rays suggestive of a malignant bone tumor

Inclusion Criteria:All patients with bone x-rays suggestive of a malignant bone tumor

Exclusion Criteria:Patients with a known diagnosis of cancer.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01047878

United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Alejandro Sweet-Cordero    650-725-5901   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Sub-Investigator: Neyssa Marina, MD         
Principal Investigator: Alejandro Sweet-Cordero, MD         
Sponsors and Collaborators
Stanford University
Principal Investigator: Alejandro Sweet-Cordero, MD Stanford University
  More Information

Responsible Party: Stanford University Identifier: NCT01047878     History of Changes
Other Study ID Numbers: PEDSSARC0001  97630  SU-12082009-4522 
Study First Received: January 11, 2010
Last Updated: April 22, 2016
Health Authority: United States: Institutional Review Board processed this record on May 24, 2016